Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 18/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632788 | 0.83 | MTOR (0.62) | MTORPIK3CA | |
| SCHEMBL8367412 | 0.82 | MTOR (0.50) | MTORPIK3CA | |
| SCHEMBL2709515 | 0.82 | MEN1 (0.54) | MTORPIK3CAMEN1ALDH1A1KMT2A | |
| SCHEMBL2632797 | 0.77 | MTOR (0.53) | MTOR | |
| SCHEMBL2632796 | 0.76 | MTOR (0.54) | MTOR | |
| SCHEMBL2632795 | 0.76 | MTOR (0.53) | MTOR | |
| SCHEMBL8369017 | 0.76 | MTOR (0.38) | MTORPIK3CAMEN1ALDH1A1KMT2A | |
| SCHEMBL2632789 | 0.73 | MTOR (0.49) | MTORPIK3CA | |
| SCHEMBL2710726 | 0.71 | MTOR (0.68) | MTORPIK3CA | |
| SCHEMBL10150263 | 0.69 | LMNA (0.56) | MTORPIK3CAMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | MTOR 1/4885PIK3CA 2/4885MEN1 3217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.